

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Oncology

**ESPS manuscript NO:** 17511

**Title:** Neoadjuvant or adjuvant therapy for gastric cancer

**Reviewer's code:** 00503460

**Reviewer's country:** Italy

**Science editor:** Ya-Juan Ma

**Date sent for review:** 2015-03-13 08:11

**Date reviewed:** 2015-03-29 15:58

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[ Y ] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

## COMMENTS TO AUTHORS

The Authors should also report the European ongoing trials on molecular targeted therapies to improve the completeness of the study. The p value should be added in the Table 1.

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Oncology

**ESPS manuscript NO:** 17511

**Title:** Neoadjuvant or adjuvant therapy for gastric cancer

**Reviewer's code:** 00068348

**Reviewer's country:** Greece

**Science editor:** Ya-Juan Ma

**Date sent for review:** 2015-03-13 08:11

**Date reviewed:** 2015-03-30 23:56

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

## COMMENTS TO AUTHORS

Gastric cancer is considered one of the most common cancer types worldwide. The majority of patients present in advanced stage and outcome still remains poor with high mortality rate despite decreasing incidence and new diagnostic and therapeutic strategies. Despite the use of well known chemotherapeutic agents, advances have been slow and the efficacy of these agents has reached a plateau of median overall survival not higher than 12 months. Regarding surgical therapy the gold standard remains R0 excision with D2 lymphadenectomy. Regarding the paper, is well written providing usefull information in the field of neoadjuvant and adjuvant therapeutics in gastric cancer. A few remarks: the authors can provide more information regarding the interaction between neoadjuvant therapies and surgical treatment options. Also the authors can refer to ongoing clinical trials running with molecular targeted therapies such as the HER-FLOT study which is a promising study running in Germany.

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Oncology

**ESPS manuscript NO:** 17511

**Title:** Neoadjuvant or adjuvant therapy for gastric cancer

**Reviewer's code:** 01551804

**Reviewer's country:** Japan

**Science editor:** Ya-Juan Ma

**Date sent for review:** 2015-03-13 08:11

**Date reviewed:** 2015-03-14 16:54

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[ Y ] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[ Y ] No	

## COMMENTS TO AUTHORS

Quéro L et al.: Neoadjuvant or adjuvant therapy for gastric cancer. (MS No. 17511) The authors broadly reviewed neoadjuvant or adjuvant therapy for advanced resectable gastric cancer in the world including the United States, Europe and East Asia. Although there is no international consensus because of the difference in surgical procedures, they summarized clinical trials based on the reports from various countries. Furthermore, ongoing randomized trials evaluating the optimal sequence of chemotherapy, radiotherapy and surgery have been included. The manuscript is well written and has important information regarding the treatment options for resectable gastric cancer; however, there are a few points of concern that preclude the manuscript from being accepted in the journal. Specific comments: Molecular targeted therapies are now a major topic for various types of cancers including advanced gastric cancer. For example, trastuzumab is currently available for gastric cancer and, therefore, the ongoing trials using targeted therapy (trastuzumab) in combination with chemotherapy, such as HER-FLOT (Germany), NEOXH (Spain) and so on, should be included in the manuscript. Moreover, the authors should discuss about the possibility of targeted therapy to improve the outcome of advanced resectable gastric cancer. Minor comments: 1. The author



## BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

<http://www.wjgnet.com>

---

should correct some misspelled words. Page 4, line 22: french – French Page 11, line 19:  
Lapatanib – Lapatinib